Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Pechala's Reports
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Valeant Pharmaceuticals International Inc Issues FY 2013 Guidance In Line With Analysts' Estimates-Conference Call

Friday, 4 Jan 2013 08:00am EST 

Valeant Pharmaceuticals International Inc announced that for fiscal 2013, it expects revenue to be in the range of $4.4 billion to $4.8 billion and EPS in the range of $5.45 to $5.75 a share. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $4.7 billion and EPS of $5.68 for fiscal 2013.